Objective-To determine the relation of cardiac autoantibody and disease status in a consecutive series of patients with dilated cardiomyopathy by prospective antibody testing at diagnosis and at follow up.
Methods-Antibody status was assessed by indirect immunofluorescence in 110 patients with dilated cardiomyopathy (85 male, mean (SD) age 44 (13) years) at diagnosis and at follow up (mean (SD) 14 (12) months); in 57 of them cardiac specific anti-a myosin antibody titres were also measured by an enzyme-linked immunosorbent assay (ELISA). Patients underwent complete evaluation at diagnosis and clinical and non-invasive assessment at follow up, including exercise testing with maximal oxygen consumption measurements. Results-The frequency of cardiac specific antibodies by immunofluorescence was lower at follow up than at diagnosis (28 (25%) v 11 (10%), P = 0.002). Mean (SEM) anti-a myosin antibody titres at follow up were also lower than at diagnosis (0.24 (0.02) v 0 30 (0.02), P = 0.038); 24% of patients at diagnosis and 14% at follow up had an abnormal ELISA result. None of the patients who were negative by immunofluorescence or ELISA at diagnosis became positive at follow up. Presence of antibody at diagnosis was associated with milder symptoms and greater exercise capacity at follow up and persistence of antibody at follow up was associated with stable disease and milder symptoms at diagnosis. Conclusions-Cardiac specific autoantibodies in dilated cardiomyopathy become undetectable with disease progression; this is a recognised feature of other autoimmune conditions, such as type 1 diabetes. Detection of these antibodies at diagnosis and at follow up may provide a non-invasive marker of early dilated cardiomyopathy.
(Heart 1997;77:62-67) Keywords: idiopathic dilated cardiomyopathy; cardiac specific antibodies; autoimmune disease; anti-myosin antibodies Dilated cardiomyopathy is a chronic heart muscle disease of unknown aetiology.' 2 The finding of circulating autoantibodies to various cardiac autoantigens provides evidence for autoimmunity in a subset of patients.3-" Indirect immunofluorescence5 or an a-myosin specific enzyme-linked immunosorbent assay (ELISA)'2 detected organ and disease specific cardiac autoantibodies at diagnosis in about a third of patients with dilated cardiomyopathy. Detection of these antibodies in 15-20% of the symptom-free relatives of such patients is further evidence for autoimmune involvement and suggests that autoimmunity may account for a even greater proportion of cases.'2 13 The autoimmune features found in dilated cardiomyopathy closely resemble insulindependent diabetes mellitus.'3 14 Islet cell antibody markers are found in most patients with type 1 diabetes at the onset of symptoms but are detected in only 30-40% of those with long-standing diabetes. '9 16 Most patients with dilated cardiomyopathy may be antibody negative at diagnosis because of a decline in antibody titres with disease progression.
To determine the relation of antibody and disease status we performed prospective antibody testing in patients with dilated cardiomyopathy at diagnosis and at follow up.
Patients and methods

STUDY TRIAL DESIGN
We studied 110 consecutive patients with dilated cardiomyopathy (mean (SD) age 44 (13), 85 male) who presented to a tertiary referral centre for heart failure and arrhythmia treatment. All patients underwent clinical assessment and cardiac antibody testing by immunofluorescence at diagnosis and at their first follow up visit (mean (SD) 14 (12) , range 1 to 74 months after diagnosis); in addition, in 57 patients anti-a myosin antibody titres were measured by ELISA at diagnosis and follow up. The ELISA measurements were performed on the same sera used for antibody detection by immunofluorescence but investigators were blinded to the immunofluorescence results. The 57 patients in whom ELISA was performed were unselected: they were those in whom enough serum was available for testing. All immunological tests were performed without knowledge of the clinical data. The study was approved by our institutional review committee and all patients gave informed consent. PROTOCOL 13 Briefly, "organ-specific" antibodies produced a diffuse cytoplasmic staining of myocytes; "cross-reactive 1" antibodies gave a fine striational immunofluorescence on cardiac tissue but stained skeletal muscle fibres only weakly; "cross-reactive 2" antibodies stained with a broad striational pattern both heart and skeletal muscle sections. Absorption studies with relevant tissues had confirmed the organ-specificity and cross-reactivity of the three antibody types.8 Antibodies of the cross-reactive 2 type are found in a small proportion of dilated cardiomyopathy cases and controls8; this finding also applied to the present study and these results are not detailed. Two sera were used as standard positive (antibody titre 1/40) and negative controls and titrated in every assay. The intensity of immunofluorescence of the positive standard at 1/40 dilution was used as the threshold for positivity. All sera tested at 1/10 dilution were read blindly against these standards. An additional positive control serum was titrated to assess reproducibility.8 End point titres for this serum were reproducible within one double dilution in all assays.
Disease and nornal controls for the immunofluorescence test Control groups for the immunofluorescence test included 301 patients (mean (SD) age 48 (11) years, 205 male) with cardiac disease other than dilated cardiomyopathy, of whom 141 had ischaemic heart failure (mean (SD) angiographic ejection fraction = 30 (8)%), and 160 had miscellaneous diseases (55 rheumatic heart disease, 67 hypertrophic cardiomyopathy, 38 congenital heart defects), and 200 healthy blood donors (age 35 (11) years, 91 male). All 200 controls and 225 of the 301 disease controls had been assessed for their antibody status and their features reported elsewhere.8
Anti-a myosin antibody testing by immunosorbent assay method Atrial tissue, obtained from one normal donor heart at the time of transplantation, was frozen in liquid nitrogen and stored at -80°C until use. The a-(atrial specific) myosin samples were prepared as described.'0 The ELISA method for detection of anti-a myosin antibodies has been reported before.'2 Briefly, ELISA plates (Immulon 1; Dynatech, W Sussex) were coated with sequential duplicates of 100 u1 purified human a-myosin at a concentration of 5 jg/ml. Sera were diluted at 1/320 in PBS (Sigma, UK) containing 01% Tween 20 and 1 % bovine serum albumin. Absorbance was assessed using a Pasteur Diagnostics ELISA reader at 450 nm. All antibody titres are expressed as mean (SEM) absorbance at 450 nm. The upper limit of normal for the assay was defined as 2 SD above the mean value obtained from the healthy controls.
Ischaemic and healthy control subjects for the immunosorbent assay. The ELISA control groups included 203 healthy individuals (age 45 (16) years, 100 .27 J 1%, P = 0-0001), in ischaemic heart failure 28 (1/141, 1%, P = 0 0001), or in healthy controls (7/200, 3%, P = 0 0001). Cardiac autoantibodies of the cross-reactive 1 type be were also more common in dilated cardiomyossopathy ( (9) 15 (9) (n = 17) (n = 12) 24 (9) 21 (10) 69 (18) 58 ( 23 (9) 60 (24) FS, fractional shortening; LVEDD, left ventricular end diastolic dimension; LVESD, systolic dimension; NYHA, New York Heart Association; O-s, organ-specific; cross-} reactive; PCWP, mean pulmonary capillary wedge pressure; EF, ejection fraction; I maximal oxygen consumption; Vo,%, Vo,max expressed as % of the predicted value. (9) 14 (7) 13 (6) 1 Angiographic EF (%)
25 (11) 24 (11) 28 (10) l PCWP (mmHg)
21 (8) 26 (8) 21 (7) 1 (n = 3) (n = 7) (n = 20) Vo2max (m/min/kg) 26 (3) 25 (7) 23 (11) 1 Vo,% 64 (8) 73 (14) 64 (27) At follow up cardiac autoantibodies of the IgG class were detected in 22 patients with dilated cardiomyopathy; 11 of them (10%) had autoantibodies of the organ-specific and 11 (10%) of the cross-reactive 1 type. Cardiac antibody titres were 1/10 in 13 sera (12%), 1/20 in five (4-5%), and 1/40 in four (4%). Autoantibodies of both the organ specific and of the cross reactive 1 types were significantly less common at follow up than at diagnosis (11 (10%) v 28 (25%) and 11 (10%) v 18 (16%) respectively; P = 0 002). Antibody titres at diagnosis and follow up in the 46 patients found to be positive at diagnosis are shown in the figure. Of these 46 patients, 22 (48%) were persistently antibody positive and 24 (52%) became negative at follow up, but none of the 64 patients who were negative at diagnosis became positive at follow up (P = 0.0001). When features at diagnosis in patients with dilated cardiomyopathy who had persistent antibodies by immunofluorescence at follow up (n = 22) were compared with those who were positive at diagnosis and became negative at follow up (n = 24) we found that milder symptoms (NYHA I-II) were more common among the patients with persistent organ-specific cardiac antibody (10, 91%) than among those without (20, 57%, P = 0 04) or among antibody negative patients (12, 50%, P = 0 02) (table 4). Fewer patients with persistent organ-specific cardiac antibody were clinically deteriorating (2, 18%) than those without (23, 66%, P = 0 005) or than antibody negative patients (17, 71%, P = 0 004). No other significant associations were found between ELISA results at follow up and features at diagnosis, or between antibody results (immunofluorescence or ELISA) at follow up and features at follow up (not shown).
Discussion
Using standardised techniques we found cardiac specific autoantibodies in 25% of patients with dilated cardiomyopathy at diagnosis and a decline in titres over time with antibody persistence in only half of the patients at one year follow up. These antibodies were uncommon in controls; this is in keeping with the findings in other autoimmune diseases15 16 20-22 and confirms our previous observations in distinct patient series. 8 23-24 The concordance between immunofluorescence and ELISA is not surprising; although the two techniques have different cut-offs, in the ELISA we used a-myosin, which is one of the autoantigens recognised by the antibodies detected by immunofluorescence. 10 Decline of autoantibody titres with disease evolution is a recognised feature of other autoimmune disorders-for example, longstanding type 1 diabetes.'5 16 Thus the reduction in autoantibody production as heart failure progresses in dilated cardiomyopathy is not an unexpected finding. Although immunofluorescence is only semiquantitative, we used a standardised technique that in our experience is reliable and highly reproducible. 8 Another finding presented here was that the detection of cardiac specific autoantibodies at diagnosis was associated with greater exercise tolerance, expressed by objective measurement of exercise capacity.'829 In fact antibody positive patients had greater Vo2% both at diagnosis or at one year follow up than those who were antibody negative; in addition Vo2% was positively related to a high antibody titre. These data strongly suggest that cardiac antibodies are early markers. The fact that mean symptom duration before diagnosis correlated poorly with antibody status is not surprising; assessment of symptoms is inferior to objective Vo2max measurements of functional capacity in evaluating disease evolution in heart failure patients. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] In addition, patients with dilated cardiomyopathy may be symptom-free or for long periods may experience few symptoms; this may also explain a relatively poor correlation at diagnosis between antibody status and symptom duration. Nevertheless, when patients who had persistently detectable antibodies at follow up were compared with those who had lost these markers, persistence of cardiac specific antibodies was associated with milder symptoms at presentation and with absence of clinical deterioration. Positive antibody status at diagnosis was also associated with milder symptoms and greater Vo2% at follow up. These findings again suggest that the antibody markers are associated with early disease. In keeping with this view is the detection of the same antibodies in symptom-free relatives of patients with dilated cardiomyopathy; these relatives had borderline left ventricular dysfunction on echocardiography."3
In conclusion, the follow up data presented in this study indicate that cardiac-specific autoantibodies in dilated cardiomyopathy become undetectable with disease progression. Patients may go through a pre-clinical period when autoantibody titres are high, but heart dysfunction is unrecognised. It is important to screen and follow up their symptom-free relatives to identify those at risk, to achieve early diagnosis and potential preventative therapeutic measures. In documented dilated cardiomyopathy, presence of antibody at diagnosis was associated with milder symptoms and greater functional capacity one year later, and antibody persistence at one year follow up was associated with stable disease and milder symptoms at diagnosis. This may provide a non-invasive adjunctive marker for patients at early disease stages, although extended longitudinal observations are needed to firmly establish the role of the antibody as a prognostic marker.
